Skip to main content

Pelthos Therapeutics Inc.

PTHS
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001919246

In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Pelthos Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
3 insiders, $55.9K in total
Insiders trading
3
Net value
−$55.9K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Pelthos Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Pelthos Therapeutics Inc.
NameTitleLast reported holdingLast filingFilings, past year
Friedberg Ezra MDirector81,042Jul 7, 20266
Pauls MatthewDirector14,364Jul 7, 20264
Greenleaf PeterDirector23,884Jul 7, 20263
Davis Todd CDirector75,834Jun 15, 20262
Francis Knuettel IICFO, Treas & Secty11,316IndirectMay 26, 20262
Malamut RichardDirector27,422Apr 6, 20262
Plesha Scott M.CEO and President83,678Apr 1, 20261
Baxter Richard BDirector19,108Apr 1, 20261
Rangarao SaiChief Commercial Officer30,518Apr 1, 20261
Einhorn Andrew J.Director12,000Dec 29, 20251
Ligand Pharmaceuticals IncDirector, 10% Owner1,500,000Dec 19, 20252
Simmons Chia-LinDirector–Apr 15, 20250
Lang EricChief Medical Officer–Jun 18, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 7, 2026 (view filing)5:03 PM ETJul 25 daysFriedberg Ezra MDirectorSSale−558$26.09−$14.6K−0.7%81.0K after2 lots10b5-1
Jul 7, 2026 (view filing)5:03 PM ETJul 25 daysPauls MatthewDirectorSSale−786$26.16−$20.6K−5.2%14.4K after2 lots10b5-1
Jul 7, 2026 (view filing)5:03 PM ETJul 25 daysGreenleaf PeterDirectorSSale−797$26.13−$20.8K−3.2%23.9K after2 lots10b5-1
Jun 17, 2026 (view filing)Jun 152 daysFriedberg Ezra MDirectorSSale−283$27.29−$7.72K−0.3%81.6K after2 lots10b5-1
Jun 15, 2026 (view filing)Jun 114 daysDavis Todd CDirectorPPurchase+35.9K$27.81+$999.8K+90.1%75.8K after2 lots
May 26, 2026 (view filing)May 224 daysFrancis Knuettel IICFO, Treas & SectySSale−1.50K$26.84−$40.3K−11.7%11.3K after
Apr 6, 2026 (view filing)Apr 24 daysMalamut RichardDirectorSSale−590$20.91−$12.3K−2.1%27.4K after2 lots10b5-1
Apr 6, 2026 (view filing)Apr 24 daysFriedberg Ezra MDirectorSSale−558$20.91−$11.7K−0.7%82.0K after2 lots10b5-1
Apr 6, 2026 (view filing)Apr 24 daysPauls MatthewDirectorSSale−786$20.92−$16.4K−4.9%15.2K after2 lots10b5-1
Apr 6, 2026 (view filing)Apr 24 daysGreenleaf PeterDirectorSSale−797$20.92−$16.7K−3.1%24.7K after2 lots10b5-1
Nov 26, 2025 (view filing)Nov 251 dayFriedberg Ezra MDirectorSSale−10.0K$28.03−$280.3K−25.0%30.0K after4 lots
Jul 3, 2025 (view filing)Jul 12 daysFriedberg Ezra MDirectorPPurchase+132.1K$0.00$0–40.0K afterDerivative2 lots
Sep 16, 2024 (view filing)Sep 124 daysMalamut RichardDirectorPPurchase+10.4K$0.94+$9.78K+12.8%91.6K after
Sep 16, 2024 (view filing)Sep 12-134 daysFrancis Knuettel IICEO, Pres., CFO, Treas & SectyPPurchase+5.20K$0.97+$5.04K+1.0%547.7K after2 lots
Sep 12, 2024 (view filing)Sep 10-112 daysFrancis Knuettel IICEO, Pres., CFO, Treas & SectyPPurchase+12.0K$0.9129+$11.0K+2.3%542.5K after2 lots
Mar 12, 2024 (view filing)Feb 2120 daysFriedberg Ezra MDirectorPPurchase+16.7K$6.00+$100.0K+3.2%545.7K afterAmended